Searched for
MESALAMINE
Sun Pharma recalls around 55k bottles of generic medication in USSun Pharma is recalling approximately 55,000 bottles of a generic medication used to treat bowel disease in the US market. The recall is du...- Alembic Pharma jumps over 6% on getting approval from USFDA for Mesalamine extended-release capsules“The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Apriso Extended-Release Capsules, 0.375 g, of ...
- Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsulesThe approved drug is therapeutically equivalent to Salix Pharmaceuticals Inc's reference listed drug (RLD), Apriso extended-release capsule...
- Sun Pharma jumps 4% on receiving USFDA nod for Mesalamine capsuleThe company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended r...
- Sun Pharma gets USFDA nod for generic drug Mesalamine extended release capsulesThe company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended r...
- Cadila Healthcare surges 10% on 4-fold jump in Q2 profit"We remain positive on Cadila on account of robust launch momentum, build-up of a complex product pipeline including injectables and transd...
- Zydus Cadila gets USFDA nod to market Mesalamine suppositoriesThis will be manufactured at the group's topical manufacturing facility at Ahmedabad.
- Cadila Healthcare Q2 profit up 32% at Rs 503 crore
- Zydus Cadila gets USFDA nod for its ulcerative colitis drugThe company has received final approval from the USFDA for Mesalamine delayed-release tablets in the strength of 800 mg, Zydus Cadila said ...
- Zydus Cadila launches anti-ulcer drug in USThe Gujarat-based group has more than 130 USFDA approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenc...
- Cadila receives audit closure reportThe Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations, the company said.
- Cadila Healthcare scales record high on USFDA approvalThe USFDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market.
- Zydus Cadila gets USFDA nod for mesalamine tabletsZydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda (mesalamine), the company s...
- US court rules in favour of Zydus Cadila in patent caseThe US Court of Appeals for the Federal Circuit has affirmed judgement in favour of Zydus Pharmaceuticals (USA) Inc.
- Lupin, Gavis to sell 2 drugs to fulfil US FTC conditionThe acquisition creates the fifth largest portfolio of abbreviated new drug application (ANDA) filings with the USFDA, addressing a USD 63....
- Government caps price of 18 formulation packsAs per the notification, the prices of formulations including Diclofenac Sodium, Clotrimazole, Mesalamine, Omeprazole+Domperidone and Vanco...
- Warner Chilcott & Cadila Healthcare settles patent litigationIndia's fifth largest drug maker by revenue, Zydus Cadila Group has settled a patent litigation with US-based Warner Chilcott Company LLC.
- Cadila Healthcare inks pact with Warner Chilcott to settle patent disputeCadila Healthcare along with Zydus Pharmaceuticals have entered into an agreement with Warner Chilcott Company to settle all outstanding pa...
- Zydus Cadila faces patent suit in US over drug AsocolUS based Warner Chilcott Plc has moved court against Zydus Cadila's plan to produce a bowel inflammation drug Asocol.
- P&G to sell global pharma biz for $3.1 bnAmerican consumer products major Procter & Gamble Company will be selling its global pharmaceuticals business to Ireland-based pharma entit...
Load More
